{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:12:57Z","timestamp":1767827577434,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.10.052","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T15:46:42Z","timestamp":1478706402000},"page":"6330-6334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged \u2a7e19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012\u2013December 31, 2015"],"prefix":"10.1016","volume":"34","author":[{"given":"Penina","family":"Haber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Arana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Pilishvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.052_b0005","unstructured":"Prevnar 13 Package insert; 2010. Available at: http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=501."},{"key":"10.1016\/j.vaccine.2016.10.052_b0010","series-title":"Use of Prevnar 13 vaccine for people ages 50 and older","year":"2011"},{"key":"10.1016\/j.vaccine.2016.10.052_b0015","series-title":"Vaccines and related biological products advisory committee (VRBPAC) adult indication briefing document: Prevnar 13","author":"Food and Drug Administration","year":"2011"},{"key":"10.1016\/j.vaccine.2016.10.052_b0020","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2016.10.052_b0025","series-title":"GRADE tables: 2014","author":"Centers for Disease Control and Prevention (CDC)","year":"2014"},{"key":"10.1016\/j.vaccine.2016.10.052_b0030","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.052_b0035","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.10.052_b0040","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4161\/hv.34420","article-title":"Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly","volume":"11","author":"Durando","year":"2015","journal-title":"Hum Vacc Immunother"},{"issue":"36","key":"10.1016\/j.vaccine.2016.10.052_b0045","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.10.052_b0050","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2016.10.052_b0055","unstructured":"Medical dictionary for regulatory activities. http:\/\/www.meddra.org\/how-to-use\/support-documentation [Accessed May 20, 2016]."},{"key":"10.1016\/j.vaccine.2016.10.052_b0060","unstructured":"International conference on harmonization of technical requirements for registration of pharmaceuticals. http:\/\/www.ich.org\/products\/meddra.html."},{"key":"10.1016\/j.vaccine.2016.10.052_b0065","unstructured":"Code of Federal Regulations. 21 CFR \u00a7600.80. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=600.80 [revised April 1, 2010]."},{"key":"10.1016\/j.vaccine.2016.10.052_b0070","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.052_b0075","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.10.052_b0080","series-title":"Adverse effects of vaccines: evidence and causality","author":"Institute of Medicine (IOM)","year":"2011"},{"issue":"2","key":"10.1016\/j.vaccine.2016.10.052_b0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.10.052_b0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain- Barr\u00e9 syndrome and Fisher syndrome: case definition and guidelines for collection, analysis and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2016.10.052_b0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain- Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"8","key":"10.1016\/j.vaccine.2016.10.052_b0100","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/cid\/ciu005","article-title":"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence","volume":"58","author":"Vellozzi","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2016.10.052_b0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.052_b0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2016.10.052_b0115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2016.10.052_b0120","unstructured":"Heron deaths: leading causes for 2014. National vital statistics reports, vol. 65, no. 5. Hyattsville (MD): National Center for Health Statistics; 2016."},{"issue":"6","key":"10.1016\/j.vaccine.2016.10.052_b0125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in U.S. infants","volume":"7370","author":"Yih","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.052_b0130","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The vaccine safety datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:26:30Z","timestamp":1718889990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16309872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":26,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16309872"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged \u2a7e19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012\u2013December 31, 2015","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}